CYP3A5 and peripheral neuropathy: For survivors of pediatric ALL, European American survivors had more vincristine‐induced peripheral neuropathy than African American survivors (p = 0.007) and more neurotoxicity‐related dose reductions (p < 0.0001) [15, 16], likely due to vincristine metabolism being impacted by CYP3A5 expression [43].